Oricell Therapeutics Secures Major Financing for CAR-T Development
Oricell Therapeutics Holdings Limited, a pioneering force in cancer immunotherapy, has successfully closed a $70 million Series C financing round. This significant funding marks a vital step for Oricell as it seeks to elevate its mission in the development of CAR-T therapies aimed at combating solid tumors.
Investment Partners and Future Directions
The Series C financing was co-led by notable investors including a significant medical and healthcare investment fund alongside Qiming Venture Partners. Additional participation came from various sources, including a sovereign wealth fund as well as multiple venture capital firms. The funds from this round are primarily aimed at bolstering Oricell's global outreach and enhancing its clinical initiatives, ultimately leading to market-ready solutions in the innovative cancer treatment sector.
Innovative Platforms Powering Progress
Oricell's cutting-edge pipeline of CAR-T cell therapies is supported by three proprietary platforms developed over the past ten years. These consist of:
- Ori®Ab: An advanced library for antibody discovery and engineering.
- Ori®Armoring: A strategy to enhance T-cell persistence alongside other essential capabilities.
- OnGo (Fast) CMC: A manufacturing solution that prioritizes rapid scalability and efficacy.
Exciting Developments in CAR-T Therapies
With demonstrated proof-of-concept clinical data across its therapy pipeline, Oricell is making strides towards becoming a leader in the CAR-T domain. The company's flagship product, Ori-C101, specifically targets GPC3 for treating advanced hepatocellular carcinoma (HCC). With successful completion of both pivotal clinical trials for Ori-C101, this therapy is on track to become the first CAR-T treatment approved for HCC globally.
Advancements Beyond Ori-C101
Oricell is not resting on its laurels. In addition to Ori-C101, the company is pioneering next-generation CAR-T therapies that incorporate multiple targets and mechanisms. One notable innovation is the secreting CAR-T therapy, OriC902, which has showcased unprecedented efficacy in patients suffering from challenging, late-stage solid tumors. The company has also initiated further studies for its cutting-edge dual-targeted in vivo CAR-T therapy.
Leadership Insights and Future Aspirations
Dr. Helen Yang, the Chairlady and CEO of Oricell, expressed gratitude towards the investors for their robust support. She highlighted the company's commitment to pushing the envelope of clinical advancements and evolving new technologies in CAR-T therapy.
Moreover, Mr. Peng Ren, Chairman of the Beijing Medical and Health Care Industry Investment Fund, underlined the team’s R&D strength and commercial vision as key elements in their investment strategy. He emphasized the growing importance of cell therapy in addressing solid tumors, thanks to Oricell's innovative approaches.
Mr. Xubo Hu, Managing Partner of Qiming Venture Partners, reflected on Oricell's journey from its inception to becoming a technology leader in the field. He admired the company’s adaptability and commitment to research and innovation in CAR-T therapies that could redefine treatment landscapes.
About Oricell Therapeutics
Oricell Therapeutics stands at the forefront of biotechnological advancements, particularly in the development of next-generation cell therapies. Their work is focused on addressing pressing needs in oncology via three established platforms: Ori®Ab for antibody discovery, Ori®Armoring for optimizing T-cell functionality, and OnGo (Fast) CMC for manufacturing. With multiple promising candidates demonstrating noteworthy clinical activity, Oricell is dedicated to driving change in the field of cancer treatment, providing hope to patients worldwide.
Frequently Asked Questions
What is the significance of the $70M funding for Oricell Therapeutics?
The $70M funding aims to enhance Oricell's global clinical initiatives and support their innovative CAR-T therapies targeting solid tumors.
What are the key projects currently under development by Oricell?
Oricell is advancing several projects including Ori-C101, a therapy aimed at hepatocellular carcinoma, and OriC902, a next-generation secreting CAR-T therapy.
Who led the recent Series C financing for Oricell?
The Series C financing was co-led by prominent healthcare investment entities, demonstrating strong investor confidence in Oricell's potential.
What is the future outlook for CAR-T therapies according to Oricell's leadership?
Leadership at Oricell maintains a optimistic outlook, showcasing their commitment to accelerating advancements in CAR-T therapies while addressing unmet medical needs in oncology.
How does Oricell stand out in the field of biotechnology?
Oricell is distinguished by its proprietary technology platforms and a focus on developing innovative therapies that target specific cancer types, thus paving the way for improved treatments.
